Carvedilol acts as a negative gating modulator of HCN channels, providing a potential additional mechanism for its beneficial heart rate-lowering effects in heart failure.
No takes yet. Share an insight, caveat, or question.
May support carvedilol preference in CHF via HCN effects; leaves open need for confirmatory trials.
Cao et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: